Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of two 80 mg febuxostat tablet formulations in healthy Thai volunteers under fasting conditions
TCTR20201221003Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of febuxostat (2 arms), sponsored by Novartis. Primary endpoints: Cmax, AUC0-t and 1 more. Started Oct 2021; status: completed.
02
Drugs
febuxostat
Beyond the preview
Go deeper on TCTR20201221003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20201221003.